Compile Data Set for Download or QSAR
maximum 50k data
Found 305 Enz. Inhib. hit(s) with Target = 'Cyclin-dependent kinase 5 activator 1 [99-307]'
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM601933(4-((6'-hydroxy-8'-oxo-7',8'-dihydro-6'H- spiro[cyc...)
Affinity DataIC50:  0.800nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525738(US11174252, Compound 33)
Affinity DataIC50:  1nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM601934(4-((7'-oxo-7',8'-dihydro-6'H- spiro[cyclohexane-1,...)
Affinity DataIC50:  1.30nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525743(US11174252, Compound 38)
Affinity DataIC50:  2nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20870(3-{2-[(thiophene-2-sulfonyl)methyl]-1,3-thiazol-4-...)
Affinity DataIC50:  2.10nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20851(7-(piperidin-1-ylcarbonyl)-3-[2-(pyridin-4-yl)-1,3...)
Affinity DataIC50:  2.70nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525729(US11174252, Compound 24)
Affinity DataIC50:  3.5nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525730(US11174252, Compound 25)
Affinity DataIC50:  3.60nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20856(4-amino-6-chloro-3-[2-(pyridin-4-yl)-1,3-thiazol-4...)
Affinity DataIC50:  3.80nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20850(7-[(4-methylpiperazin-1-yl)carbonyl]-3-[2-(pyridin...)
Affinity DataIC50:  4.40nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20848(3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-7-(trifluoro...)
Affinity DataIC50:  6.30nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525750(US11174252, Compound 437)
Affinity DataIC50:  7.70nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20849(N-[2-(dimethylamino)ethyl]-N-ethyl-2-oxo-3-[2-(pyr...)
Affinity DataIC50:  8.30nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20869(3-{2-[(pyridine-2-sulfonyl)methyl]-1,3-thiazol-4-y...)
Affinity DataIC50:  10nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20855(4-amino-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2-...)
Affinity DataIC50:  11nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20847(6-chloro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50:  11nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM601935(4-((3'-oxo-2',3'-dihydro-1'H- spiro[cyclohexane-1,...)
Affinity DataIC50:  14nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20832(7-fluoro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50:  16nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM601938((R)-4-((6'-(fluoromethyl)-8'-oxo- 7',8'-dihydro-6'...)
Affinity DataIC50:  17nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7492(3-[(2Z,3E)-3-(hydroxyimino)-2,3-dihydro-1H-indol-2...)
Affinity DataIC50:  20nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7264(2,3-dimethoxy-9-nitropaullone | 4,5-dimethoxy-14-n...)
Affinity DataIC50:  21nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20866(3-[2-(4-hydroxyphenyl)-1,3-thiazol-4-yl]-1,2-dihyd...)
Affinity DataIC50:  24nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525755(US11174252, Compound 442)
Affinity DataIC50:  27nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7491((4Z)-4-(2-amino-5-oxo-3,5-dihydro-4H-imidazol-4-yl...)
Affinity DataIC50:  28nMpH: 7.2 T: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20868(3-{2-[(benzenesulfonyl)methyl]-1,3-thiazol-4-yl}-1...)
Affinity DataIC50:  29nMT: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7269(3-(6-oxo-9-trifluoromethyl-5,6,7,12-tetrahydro-ind...)
Affinity DataIC50:  33nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20843(methyl 2-oxo-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]...)
Affinity DataIC50:  33nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM525749(US11174252, Compound 436)
Affinity DataIC50:  38nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20833(7-bromo-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2,...)
Affinity DataIC50:  38nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7262(14-nitro-8,18-diazatetracyclo[9.7.0.0^{2,7}.0^{12,...)
Affinity DataIC50:  40nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMedDrugBank

TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7263(9-cyanopaullone | 9-oxo-8,18-diazatetracyclo[9.7.0...)
Affinity DataIC50:  44nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20861(3-[2-(pyridin-3-yl)-1,3-thiazol-4-yl]-1,2-dihydroq...)
Affinity DataIC50:  50nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20842(3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2-dihydroq...)
Affinity DataIC50:  54nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7424((2 Z,3 E)-5,6-Dichloroindirubin-3 -oxime | 5,6-dic...)
Affinity DataIC50:  60nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7265(4,5-dimethoxy-9-oxo-8,18-diazatetracyclo[9.7.0.0^{...)
Affinity DataIC50:  60nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/[gamma-32P] ATP. 32P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM27218((2R)-2-({4-[(3-chlorophenyl)amino]-8-(propan-2-yl)...)
Affinity DataIC50:  60nMpH: 7.5 T: 2°CAssay Description:In vitro kinase assay using purified enzyme, was incubated at 30 °C with substrate, and test compounds in the presence of 15 uM ATP/ [gamma-33P]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20838(7-(morpholin-4-ylmethyl)-3-[2-(pyridin-4-yl)-1,3-t...)
Affinity DataIC50:  62nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM601939((S)-4-((6'-methyl-8'-oxo-7',8'- dihydro-6'H-spiro[...)
Affinity DataIC50:  62nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7330(2-Methoxy-9-nitro-7,12-dihydro-indolo[3,2-d][1]ben...)
Affinity DataIC50:  70nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM27217((2R)-2-{[4-(benzylamino)-8-(propan-2-yl)pyrazolo[1...)
Affinity DataIC50:  70nMpH: 7.5 T: 2°CAssay Description:In vitro kinase assay using purified enzyme, was incubated at 30 °C with substrate, and test compounds in the presence of 15 uM ATP/ [gamma-33P]...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20830(6-fluoro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50:  72nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM27216((2R)-2-({6-[(3-chlorophenyl)amino]-9-(propan-2-yl)...)
Affinity DataIC50:  75nMpH: 7.5 T: 2°CAssay Description:In vitro kinase assay using purified enzyme, was incubated at 30 °C with substrate, and test compounds in the presence of 15 uM ATP/ [gamma-33P]...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20820(3-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]-1,2,3,4-tetr...)
Affinity DataIC50:  77nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20819(3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2,3,4-tetr...)
Affinity DataIC50:  79nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7401((2 Z,3 E)-6-Bromoindirubin-3 -oxime | (3E)-6-bromo...)
Affinity DataIC50:  83nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7407((2 Z,3 E)-6-Chloroindirubin-3 -oxime | 6-chloro-3-...)
Affinity DataIC50:  100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7425((2 Z,3 E)-5,6-Dichloroindirubin-3 -acetoxime | 6,5...)
Affinity DataIC50:  100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7340(13-nitro-3-thia-7,17-diazatetracyclo[8.7.0.0^{2,6}...)
Affinity DataIC50:  100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM7393(3-[(2Z,3E)-3-(hydroxyimino)-2,3-dihydro-1H-indol-2...)
Affinity DataIC50:  100nMT: 2°CAssay Description:Kinase activities were assayed in buffers containing substrate, enzyme, and inhibitor at 30 °C in the presence of 15 uM ATP/ [gamma-32P] ATP. 32...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 5 activator 1 [99-307](Homo sapiens (Human))
G1 Therapeutics

US Patent
LigandPNGBDBM20846(6-fluoro-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,2...)
Affinity DataIC50:  110nMpH: 7.5 T: 2°CAssay Description:In vitro CDK assay using purified enzyme, was incubated at 25 °C with substrate, and test compounds in the presence of ATP/ [gamma-33P] ATP. 33P...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 305 total ) | Next | Last >>
Jump to: